Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

2.4K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.4K
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

1.3K
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
1.3K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

619
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
619
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

1.3K
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Scleroderma Clinical Trials Consortium (SCTC) outcome instruments for evaluation of systemic sclerosis.

Journal of scleroderma and related disorders·2026
Same author

Systemic sclerosis-associated pulmonary arterial hypertension and pulmonary fibrosis: exploring biomarker discriminators with advanced omics in a Caucasian cohort.

Frontiers in immunology·2026
Same author

Hospital Variations in Time-To-Crisis-Resolution Among Children and Adolescents With Sickle Cell Disease.

American journal of hematology·2025
Same author

EULAR recommendations for a core dataset to support clinical care and translational and observational research in systemic lupus erythematosus.

Annals of the rheumatic diseases·2025
Same author

Risk factors of cognitive function impairment in patients with systemic sclerosis.

Clinical and experimental rheumatology·2025
Same author

Case-Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease.

Arthritis & rheumatology (Hoboken, N.J.)·2025

Related Experiment Video

Updated: May 7, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

22.1K

Ten years EULAR Scleroderma Research and Trials (EUSTAR): what has been achieved?

Ulf Müller-Ladner1, Alan Tyndall, Laszlo Czirjak

  • 1Department of Rheumatology and Clinical Immunology, Justus-Liebig University Giessen, Kerckhoff Clinic, , Bad Nauheim, Germany.

Annals of the Rheumatic Diseases
|October 15, 2013
PubMed
Summary

The European League Against Rheumatism (EULAR) Scleroderma Trials And Research (EUSTAR) initiative established a large database for systemic sclerosis research. This fostered knowledge sharing and innovative studies for rare disease patients.

Keywords:
EpidemiologyOutcomes researchPatient perspectiveQualitative researchSystemic Sclerosis

More Related Videos

Vessel-sparing Excision and Primary Anastomosis
08:09

Vessel-sparing Excision and Primary Anastomosis

Published on: January 7, 2019

11.0K
ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection
05:57

ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection

Published on: February 10, 2017

8.2K

Related Experiment Videos

Last Updated: May 7, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

22.1K
Vessel-sparing Excision and Primary Anastomosis
08:09

Vessel-sparing Excision and Primary Anastomosis

Published on: January 7, 2019

11.0K
ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection
05:57

ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection

Published on: February 10, 2017

8.2K

Area of Science:

  • Rheumatology
  • Rare Diseases
  • Clinical Research

Background:

  • Systemic sclerosis is a rare and debilitating autoimmune disease.
  • Limited research and data hindered effective characterization and treatment development.
  • A need existed for a collaborative international network to address these challenges.

Purpose of the Study:

  • To establish a large-scale database for systemic sclerosis (SSc).
  • To facilitate precise characterization of SSc.
  • To disseminate knowledge and stimulate innovative research for SSc patients.

Main Methods:

  • Creation of a large-scale, international database.
  • Initiation of over 40 investigator-driven clinical and basic science projects.
  • Organization of multicenter European grants and educational programs.

Main Results:

  • Established a comprehensive database for systemic sclerosis.
  • Facilitated over 40 research projects.
  • Trained over 400 young clinicians in SSc management.
  • Secured multicenter European research grants.

Conclusions:

  • The EUSTAR initiative successfully created a valuable resource for SSc research.
  • The network has significantly advanced knowledge and research in systemic sclerosis.
  • EUSTAR has fostered collaboration and education, benefiting patients with this rare disease.